J&J Outlines Novel Cancer Strategy During Business Update
This article was originally published in The Pink Sheet Daily
Executive Summary
Newly approved Zytiga, for prostate cancer, loses U.S. exclusivity in 2016, but J&J looks to ex-U.S. approvals for market protection.